- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDA Issues Warning About Thermography
Thermography not a replacement for mammography
The Food and Drug Administration (FDA) today released a consumer warning that thermography should not be used in place of mammography for breast cancer screening or diagnosis.
The FDA says mammography- an X-ray of the breast-is still the most effective way of detecting breast cancer in its earliest stages. The wanring does not mention digital mammogrpahy or other modalities.
While thermography is cleared by FDA for use as an adjunct, or additional tool, it should not be used by itself to screen for, or diagnose, breast cancer, the agency clarifies.
Learn more about the FDA's concerns about the use of thermography as a screening tool at
http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm257499.htm
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.
Is the Kaiser Score More Effective than BI-RADS for Assessing Contrast-Enhanced Mammography and MRI?
October 14th 2024For women with breast-enhanced masses, Kaiser scoring (KS) demonstrated a 20 percent higher AUC than BI-RADS classification for contrast-enhanced mammography (CEM) and was comparable to KS for breast MRI.
FDA Clears New Features in AI-Powered Mammography Software Suite
October 11th 2024Therapixel’s MammoScreen suite has received 510(k) FDA clearances for a breast density assessment feature and updated software that includes automated pre-reporting, which reportedly expedites reporting of mammography findings.
